Drugs / RDN-929
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03963973 | May 2019 → Jan 2020 | — | Alkermes, Inc. | Terminated | No outcome recorded |
| Phase 1 | NCT03668314 | Oct 2018 → Apr 2019 | — | Alkermes, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RDN-929 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03668314 ↗ |
| Route | Oral | “Orally Administered RDN-929” NCT03668314 ↗ |